Drug Profile
Research programme: antibody-drug conjugates - Oxford BioTherapeutics/Seagen
Alternative Names: OX 004Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Oxford BioTherapeutics; Seattle Genetics
- Developer Oxford BioTherapeutics; Seagen
- Class Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 08 Oct 2020 Seattle Genetics is now called Seagen
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in United Kingdom (Parenteral)
- 09 May 2014 Preclinical trials in Ovarian cancer in United Kingdom (Parenteral)